REGENXBIO
Develops one-time AAV gene therapies while licensing its NAV vector platform.
Something off on this page? Send us feedback.
Profile
Develops investigational AAV gene therapies for rare and retinal diseases and licenses its NAV vector technology to partners. Its model combines internal programs with partner-linked royalty economics, including commercial products from Novartis.
Develops investigational one-time AAV gene therapies using its proprietary NAV Technology Platform. Its lead programs span retinal disease, Duchenne muscular dystrophy, and MPS I and II, including sura-vec/ABBV-RGX-314, RGX-202, RGX-121, and RGX-111.
The business pairs internal research, clinical development, manufacturing, and commercialization capabilities with selective licensing of NAV technology and related IP. Zolgensma and Itvisma use the NAV platform, making Novartis-linked royalties an important part of the model.
AbbVie collaborates on sura-vec for retinal disease, while Nippon Shinyaku partners on the MPS programs in specified territories. Program progress depends on clinical evidence, manufacturing, regulatory interactions, and collaborators.
Company facts
Key statistics
Year to date −28.7% · Average volume (30d) 1.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 25, 2026 | H.C. Wainwright | Target | $23 | $21 | ||
| Aug 25, 2026 | Robert W. Baird | Target | $32 | $29 | ||
| Aug 10, 2026 | H.C. Wainwright | Reiterate | Buy | $26 | $23 | |
| Aug 7, 2026 | Morgan Stanley | Reiterate | Overweight | $16 | $18 | |
| Aug 7, 2026 | Barclays | Downgrade | Overweight | Positive |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $0.08 | $0.43 | +446.2% | $97.6M | $108.0M | +10.6% | +7.43% |
| May 14, 2026Q1 FY26 | −$1.36 | −$1.72 | −26.5% | $25.8M | $6.4M | −75.3% | −8.48% |
| Mar 5, 2026Q4 FY25 | −$1.01 | −$1.30 | −28.7% | $44.0M | $30.3M | −31.0% | −0.80% |
| Nov 6, 2025Q3 FY25 | −$1.38 | −$1.20 | +13.0% | $59.3M | $29.7M | −49.8% | +0.36% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $89.0M | $21.4M | $29.7M | $30.3M | $6.4M | $108.0M | |
| Gross profit | $85.6M | $12.2M | −$32.1M | $24.4M | −$4.7M | $107.0M | |
| Operating income | $12.1M | −$63.3M | −$52.4M | −$57.6M | −$83.4M | $29.3M | |
| Net income | $6.1M | −$70.9M | −$61.9M | −$67.1M | −$90.1M | $22.7M | |
| Diluted EPS | $0.12 | −$1.38 | −$1.20 | −$1.30 | −$1.72 | $0.43 | |
| Gross margin | 96.1% | 57.3% | -107.9% | 80.5% | -73.2% | 99.0% | |
| Operating margin | 13.6% | -296.3% | -176.3% | -190.0% | -1,304.0% | 27.1% |
Fiscal years (4-quarter sums)FY21 $470.3M · FY22 $112.7M · FY23 $90.2M · FY24 $83.3M · FY25 $170.4M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $105.5M · Total debt $69.0M · Total assets $386.6M · Shareholders' equity $71.8M
Dividends
No dividends on record.
Ownership
Shares outstanding 51.70M · Float 44.45M · 86.0% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.40M | 12.37% | 13F | Aug 7, 2026 |
| Redmile Group, LLC | 4.37M | 8.45% | 13F | Aug 14, 2026 |
| State Street Corp | 2.97M | 5.75% | 13F | Aug 7, 2026 |
| JPMorgan Chase & Co | 2.21M | 4.28% | 13F | Aug 12, 2026 |
| Vanguard Capital Management LLC | 2.11M | 4.08% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Gregory Austin Ciongoli | director | +53,407 | $9.36 |
| Aug 26, 2026 | Gregory Austin Ciongoli | director | +49,196 | $9.14 |
| Jul 2, 2026 | Steve Pakola | officer: Chief Medical Officer | −2,161 | $13.64 |
| Jul 1, 2026 | Steve Pakola | officer: Chief Medical Officer | −36,725 | $12.86 |
| Jun 29, 2026 | Steve Pakola | officer: Chief Medical Officer | −19,608 | $11.04 |
Peers
- 4D Molecular Therapeutics
Phase 3 intravitreal gene therapy developer for wet AMD
- Sarepta Therapeutics
Commercial AAV micro-dystrophin gene therapy for Duchenne
- Solid Biosciences
Late-stage AAV micro-dystrophin developer for Duchenne
- MeiraGTx
AAV retinal gene-therapy developer with a wet AMD program
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| REGENXBIO | $9.65 | −0.21% | $499.4M | — | — | 2.9 | +405.7% |
| 4D Molecular Therapeutics | $14.67 | +0.07% | $766.9M | — | — | 8.3 | +25,106.7% |
| Sarepta Therapeutics | $21.05 | +0.98% | $2.20B | — | 26.3 | 1.1 | −34.3% |
| Solid Biosciences | $9.77 | −0.10% | $961.9M | — | — | — | — |
| MeiraGTx | $13.82 | 0.00% | $1.28B | 19.5 | — | 3.2 | +8,608.6% |
| Median | 19.5 | 26.3 | 3.2 | +8,608.6% |